The University of Southampton
University of Southampton Institutional Repository

Rosuvastatin alone or with extended-releasen niacin: a new therapeutic option for patients with combined hyperlipidemia

Record type: Article

Combination therapy with a statin and niacin may provide optimal therapy for patients with combined hyperlipidemia and low levels of high-density lipoprotein (HDL) cholesterol. The authors assessed the efficacy and safety of rosuvastatin monotherapy, extended-release (ER) niacin monotherapy, or rosuvastatin and ER niacin combined therapy in patients with atherogenic dyslipidemia. In a 24-week, open-label, multicenter trial, men and women aged ?18 years with fasting levels of total cholesterol ?200 mg/dL, HDL cholesterol ?45 mg/dL, triglycerides 200-800 mg/dL, and apolipoprotein B ?110 mg/dL were randomly assigned to one of four treatment groups: rosuvastatin 10-40 mg, ER niacin 0.5-2 g, rosuvastatin 40 mg plus ER niacin 0.5-1 g, or rosuvastatin 10 mg plus ER niacin 0.5-2 g. Daily doses of rosuvastatin 40 mg monotherapy reduced low-density lipoprotein (LDL) cholesterol and non-HDL cholesterol levels significantly more than did either ER niacin 2 g monotherapy or rosuvastatin 10 mg combined with ER niacin 2 g. Addition of ER niacin 1 g to rosuvastatin 40 mg did not further reduce total or non-HDL cholesterol. Triglyceride reductions were similar among the four treatment groups. ER niacin mono- and combined therapy produced significantly greater rises in HDL cholesterol and apolipoprotein A-1 than did rosuvastatin monotherapy. Rosuvastatin monotherapy was better tolerated than ER niacin taken either alone or with rosuvastatin. In this study, rosuvastatin very effectively improved the three major lipoprotein-lipid abnormalities of combined hyperlipidemia.

Full text not available from this repository.

Citation

Capuzzi, David M., Morgan, John M., Carey, Christina M., Intenzo, Charles, Tulenko, Thomas, Kearney, Dana, Walker, Kalen and Cressman, Michael D. (2004) Rosuvastatin alone or with extended-releasen niacin: a new therapeutic option for patients with combined hyperlipidemia Preventive Cardiology, 7, (4), pp. 176-181.

More information

Published date: 2004
Additional Information: ID: 3217

Identifiers

Local EPrints ID: 25347
URI: http://eprints.soton.ac.uk/id/eprint/25347
ISSN: 1520-037X
PURE UUID: 367460ef-24ef-4771-ace7-680345aa6d23

Catalogue record

Date deposited: 11 Apr 2006
Last modified: 17 Jul 2017 16:11

Export record

Contributors

Author: David M. Capuzzi
Author: John M. Morgan
Author: Christina M. Carey
Author: Charles Intenzo
Author: Thomas Tulenko
Author: Dana Kearney
Author: Kalen Walker
Author: Michael D. Cressman

University divisions


Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×